Portfolio company
LyGenesis
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
1 investor
Sectors
About
LyGenesis develops regenerative cell therapies that use lymph nodes as bioreactors to grow functioning organs for patients with end-stage organ failure.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
eGenesis
This company develops genetically engineered pig organs for patients suffering from organ failure and requiring transplantation.
Tengion Inc
This regenerative medicine company develops replacement organs and tissues using a patient's own cells for individuals with urologic, renal, gastrointestinal, and vascular diseases.
Trestle Biotherapeutics
This company develops implantable bioengineered kidney tissues to restore renal function for patients suffering from end-stage renal disease.
iOrganBio
This company develops an artificial intelligence-guided manufacturing platform to produce engineered human cells and organoids for biopharmaceutical researchers and clinical partners.
Thymmune
This biotechnology company develops scalable thymic cell therapies to restore immune function for patients with immunodeficiencies, autoimmune disorders, and transplant-related conditions.
Orgonex
Orgonex develops automated bioreactor systems for organoid cultivation to assist researchers and pharmaceutical companies with large-scale cell expansion and drug development.
CuroTis
This biotechnology company develops regenerative grafts that stimulate the body to grow patient-specific blood vessels for individuals requiring vascular access or organ regeneration.
Revalia
This company provides a platform for testing drug candidates on functional human organs to provide preclinical data for pharmaceutical and biotechnology firms.
